YAHOO FINANCE CHARTBOOK

44 charts that explain markets and the economy right now

Berlin - Delayed Quote EUR

Savara Inc (YB4P.BE)

2.6600

+0.1400

+(5.56%)

At close: January 31 at 8:08:30 AM GMT+1

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for YB4P.BE

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company

Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)

Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)

Savara Announces New Employment Inducement Grant

Savara Announces New Employment Inducement Grant

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate

Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate

Savara Announces Participation in Upcoming Healthcare Conferences

Savara Announces Participation in Upcoming Healthcare Conferences

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update